Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B

A single administration of scAAV2/8-LP1-hFIXco gene therapy resulted in durable factor IX expression, sustained clinical benefit, and no late-onset safety concerns over a period of 13 years. These data support the long-term efficacy and safety of AAV gene therapy for severe hemophilia B. (Funded by the U.K. Medical Research Council and others; ClinicalTrials.gov number, NCT00979238; EudraCT number, 2005-005711-17.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-06-11
DOI
https://doi.org/10.1056/nejmoa2414783
Citations
29
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
52.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B

Anne Riddell, Ellis J. Neufeld, Vincent Muczynski, Malo Journou et al.
29 citations
New England Journal of Medicine
Virus-based gene therapy research
52.70
article

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B

Anne Riddell, Ellis J. Neufeld, Vincent Muczynski, Malo Journou, Michael Recht, Randall T. Hayden, Victoria Okhomina, Andrew M. Hall, Jenny McIntosh, Edward G. D. Tuddenham, Yu‐Min Shen, Sarah Mangles, Ulrike M. Reiss, Andrew M. Davidoff, Pratima Chowdary, Christopher L. Morton, Kathleen G. Halka, Guolian Kang, Arnulfo Pie, Kristina M. Haley, Gail Fortner, Johnny Ndoni Mahlangu, Saira Mohamed, Alberto Quaglia, Amit Nathwani, Zhengming Gu, Lydia Ireland, Giulia Simini
article en
29 citations

Abstract

A single administration of scAAV2/8-LP1-hFIXco gene therapy resulted in durable factor IX expression, sustained clinical benefit, and no late-onset safety concerns over a period of 13 years. These data support the long-term efficacy and safety of AAV gene therapy for severe hemophilia B. (Funded by the U.K. Medical Research Council and others; ClinicalTrials.gov number, NCT00979238; EudraCT number, 2005-005711-17.).

New England Journal of MedicineVol. 392(22)
St. Jude Children's Research Hospital (US), Oregon Health & Science University (US), University of the Witwatersrand (ZA), Johannesburg Hospital (ZA), The Royal Free Hospital (GB), Cancer Institute (WIA) (IN), Yale University (US), Basingstoke and North Hampshire Hospital (GB), Baylor Scott & White Health (US), University College London (GB), The University of Texas Southwestern Medical Center (US)
National Institutes of Health, Medical Research Council, Horizon 2020, National Heart, Lung, and Blood Institute
Good health and well-being
Openalex Percentile: Top 0%
Virus-based gene therapy research
52.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.